<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02107885</url>
  </required_header>
  <id_info>
    <org_study_id>DS1971-A-E101</org_study_id>
    <nct_id>NCT02107885</nct_id>
  </id_info>
  <brief_title>Single Ascending Dose Study Using DS-1971 to Assess Safety, Tolerability, and Pharmacokinetics in Healthy Participants.</brief_title>
  <official_title>A Phase 1, Double-blind, Randomized, Placebo-controlled Single Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DS-1971a in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomised, double-blind, placebo-controlled and ascending single dose study. It is
      hypothesised that single oral doses of DS-1971a within the planned dose range will be safe
      and well tolerated by healthy male subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>safety and tolerability adverse events</measure>
    <time_frame>20 days after dose</time_frame>
    <description>determine number, type, and severity of adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>safety and tolerability physical exam</measure>
    <time_frame>20 days after dose</time_frame>
    <description>determine adverse changes in vital signs, ECG.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>safety and tolerability laboratory blood and urine tests</measure>
    <time_frame>from day 1 through 20 days after dose</time_frame>
    <description>determine adverse changes in laboratory safety tests of blood (biochemistry and haematology) and urine.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>plasma concentration AUC</measure>
    <time_frame>day 4</time_frame>
    <description>concentration in blood measured as Area under the curve (AUC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>maximum blood concentration</measure>
    <time_frame>day 4</time_frame>
    <description>Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time of maximum blood concentration</measure>
    <time_frame>day 4</time_frame>
    <description>T_max</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>half-life of drug in body</measure>
    <time_frame>day 4</time_frame>
    <description>T_1/2</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Safety</condition>
  <condition>Tolerability</condition>
  <condition>Pharmacokinetics</condition>
  <arm_group>
    <arm_group_label>DS-1971</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single ascending dose of 5mg, 10mg, 30mg, 90mg, 250mg, 500mg, 1000mg, 1500mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo matching each of the DS-1971 dosages.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DS-1971</intervention_name>
    <description>6 subjects in each group will receive DS-1971.</description>
    <arm_group_label>DS-1971</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>2 subjects in each group will receive placebo.</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male subjects aged 18-45 years.

          -  A body mass index (BMI or Quetlet index) in the range 18-30 kg/m^2, inclusive, and
             weighing between 50 and 100 kg at screening.

        Body Mass Index (BMI) =weight[kg] / (height [m])^2

          -  Willing to use a reliable method of contraception and not donate sperm during the
             study, and for 4 months afterwards.

          -  Sufficient intelligence to understand the nature of the study and any hazards of
             participating in it. Ability to communicate satisfactorily with the Investigator and
             to participate in, and comply with requirements of, the entire study.

          -  Willing to give written consent to participate in the study after reading the ICF, and
             after having the opportunity to discuss the study with the Investigator or his
             delegate.

          -  Willing to give written consent to have his data entered into The Over-volunteering
             Prevention System.

        Exclusion Criteria:

          -  Clinically relevant abnormal history, physical findings, ECG findings, or laboratory
             values that could interfere with the objectives of the study or compromise the safety
             of the subject.

          -  Presence or history of acute or chronic illness, including (but not limited to) liver
             or kidney disease, hypertension, seizures, or any known impairment of endocrine, or
             other specific body-organ dysfunction.

          -  History of serious reaction to any medicine.

          -  Presence or history of malignant disease.

          -  Acute or chronic infectious disease, including HIV, HBV or HCV infection.

          -  Surgery (e.g. stomach bypass) or medical condition that might affect how the body
             handles or absorbs medicines.

          -  Significant illness within 4 weeks before the dose of trial medication.

          -  Participation in another clinical trial of a new chemical entity or a prescription
             medicine within the previous 3 months, or unwilling to abstain from participating in
             other clinical trials during the study and for 3 months after receipt of trial
             medication.

          -  Abnormal ECG waveform morphology at screening that would preclude accurate measurement
             of the QT interval duration.

          -  QTcF interval duration &gt; 430 msec, obtained as an average from the 3 ECG measurements
             on the triplicate screening ECGs.

          -  Estimated glomerular filtration rate (eGFR) &lt; 90 mL/min/1.73m^2MDRD] equation).

          -  Use of any prescription or OTC medications known to be strong inhibitors or strong
             inducers of CYP enzymes (also known as CYP P450 enzymes) during the 30 days before the
             dose of trial medication; use of any other prescription or OTC medicine including
             vitamins or herbal remedies like St John's wort, with the exception of acetaminophen
             (paracetamol), during the 7 days before the dose of trial medication.

          -  Consumption of grapefruit, grapefruit juice or Seville oranges within 10 days before
             the dose of trial medication, or unwilling to abstain from consuming them throughout
             the study.

          -  Consumption of food or beverages containing caffeine or xanthine within 24 h before
             admission on Day -1, or unwilling to abstain from consuming them for 3 days after
             receiving the trial medication.

          -  Loss of more than 400 mL blood during the 3 months before the study.

          -  Donation of blood, plasma, platelets, or any other blood components during the 3
             months before the study, or unwilling to abstain from doing so during the study and
             for 3 months after receipt of trial medication.

          -  Abuse of drugs or alcohol during the 2 years before the dose of trial medication, or
             intake of more than 21 units of alcohol weekly.

          -  Use of tobacco products or nicotine-containing products during the 3 months before the
             dose of trial medication.

          -  Evidence of drug or alcohol abuse at screening or admission.

          -  Likely possibility that the volunteer will not cooperate with the requirements of the
             protocol.

          -  Objection by GP to the volunteer entering the study.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hammersmith Medicines Research Ltd.</name>
      <address>
        <city>London</city>
        <zip>NW10 7EW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2014</study_first_submitted>
  <study_first_submitted_qc>April 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2014</study_first_posted>
  <last_update_submitted>October 16, 2014</last_update_submitted>
  <last_update_submitted_qc>October 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

